Literature DB >> 31740570

Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.

Katherine R Tuttle1,2, David Z Cherney3.   

Abstract

Entities:  

Keywords:  SGLT2 inhibitor; anti-hyperglycemic therapies; chronic kidney disease; diabetes; diabetic nephropathy; hypoglycemic agents; kidney disease; sodium-glucose transporter 2

Mesh：

Substances：

Year:  2019        PMID： 31740570      PMCID： PMC7015086          DOI： 10.2215/CJN.07730719

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Authors:  Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Fady T Botros; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles Messan Atisso; Leanne Dyal; Stephanie Hall; Purnima Rao-Melacini; Gloria Wong; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto German Cardona Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet       Date:  2019-06-09       Impact factor: 79.321

3.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

Review 4.  11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

5.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Authors:  Radica Z Alicic; Michele T Rooney; Katherine R Tuttle
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 8.237

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Authors:  Katherine R Tuttle; Mark C Lakshmanan; Brian Rayner; Robert S Busch; Alan G Zimmermann; D Bradley Woodward; Fady T Botros
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-14       Impact factor: 32.069

8.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

9.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

10.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245
  10 in total
  10 in total

Review 1.  Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease.

Authors:  Connie M Rhee; Kamyar Kalantar-Zadeh; Katherine R Tuttle
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-01-01       Impact factor: 2.894

2.  Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.

Authors:  Katherine R Tuttle; Leslie Wong; Wendy St Peter; Glenda Roberts; Janani Rangaswami; Amy Mottl; Alan S Kliger; Raymond C Harris; Patrick O Gee; Kevin Fowler; David Cherney; Frank C Brosius; Christos Argyropoulos; Susan E Quaggin
Journal:  Clin J Am Soc Nephrol       Date:  2022-06-01       Impact factor: 10.614

3.  Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.

Authors:  Min Zhuo; Jiahua Li; Leo F Buckley; Sri Lekha Tummalapalli; David B Mount; David J R Steele; David J Lucier; Mallika L Mendu
Journal:  Kidney360       Date:  2022-01-19

Review 4.  Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review.

Authors:  Lisa Dubrofsky; Anand Srivastava; David Z Cherney
Journal:  Can J Kidney Health Dis       Date:  2020-06-24

Review 5.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

6.  A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes.

Authors:  Lisa Dubrofsky; Jason F Lee; Parisa Hajimirzarahimshirazi; Hongyan Liu; Alanna Weisman; Patrick R Lawler; Michael E Farkouh; Jacob A Udell; David Z Cherney
Journal:  Can J Kidney Health Dis       Date:  2022-02-28

7.  Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study.

Authors:  Samantha T Harris; Elisabetta Patorno; Min Zhuo; Seoyoung C Kim; Julie M Paik
Journal:  Diabetes Care       Date:  2021-08-03       Impact factor: 17.152

Review 8.  Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Authors:  Carolina Lavoz; Sandra Rayego-Mateos; Macarena Orejudo; Lucas Opazo-Ríos; Vanessa Marchant; Laura Marquez-Exposito; Antonio Tejera-Muñoz; Juan F Navarro-González; Alejandra Droguett; Alberto Ortiz; Jesús Egido; Sergio Mezzano; Raúl R Rodrigues-Diez; Marta Ruiz-Ortega
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

Review 9.  Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Richard O Day; Jerry R Greenfield
Journal:  Drug Saf       Date:  2020-10-23       Impact factor: 5.606

10.  Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.

Authors:  Yan Xie; Benjamin Bowe; Andrew K Gibson; Janet B McGill; Yan Yan; Geetha Maddukuri; Ziyad Al-Aly
Journal:  Diabetes Care       Date:  2020-09-10       Impact factor: 17.152
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.